CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Analyst Reco. Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Market Closed - Nyse Other stock markets 04:00:02 2024-05-03 pm EDT			5-day change	1st Jan Change
233.5 ^USD	+1.56%		+1.94%	-1.24%

Apr. 25	FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids	CI
Apr. 24	Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zacks Investment Research Adjusts Charles River Laboratories International's Price Target to $259 From $278	Apr. 12	MT
Charles River Laboratories Signs Plasmid DNA Manufacturing Deal With Ship of Theseus	Apr. 04	MT
Deutsche Bank Raises Price Target on Charles River Laboratories to $300 From $275, Keeps Buy Rating	Mar. 22	MT
Argus Raises Price Target on Charles River Laboratories International to $290 From $200, Maintains Buy Rating	Mar. 18	MT
Deutsche Bank Raises Charles River Laboratories International Price Target to $275 From $245, Maintains Buy Rating	Feb. 16	MT
Morgan Stanley Raises Price Target on Charles River Laboratories International to $235 From $205, Keeps Equalweight Rating	Feb. 16	MT
TD Cowen Adjusts Charles River Laboratories International's PT to $260 From $193, Keeps Market Perform Rating	Feb. 15	MT
Stephens Adjusts Charles River Laboratories International's PT to $280 From $270, Keeps Overweight Rating	Feb. 15	MT
Citigroup Adjusts Price Target on Charles River Laboratories International to $250 From $215, Maintains Neutral Rating	Feb. 15	MT
UBS Adjusts Charles River Laboratories International Price Target to $290 From $270, Maintains Buy Rating	Feb. 15	MT
JPMorgan Adjusts Price Target on Charles River Laboratories International to $280 From $270, Maintains Overweight Rating	Feb. 15	MT
Baird Adjusts Price Target on Charles River Laboratories International to $268 From $252, Maintains Outperform Rating	Feb. 15	MT
Guggenheim Downgrades Charles River Laboratories International to Neutral From Buy	Feb. 15	MT
Futures climb after Wall St sell-off; rate-cut jitters loom	Feb. 14	RE
UBS Adjusts Charles River Laboratories International Price Target to $270 From $215, Maintains Buy Rating	Dec. 15	MT
Citigroup Adjusts Price Target on Charles River Laboratories to $215 From $190, Keeps Neutral Rating	Dec. 11	MT
Morgan Stanley Cuts Price Target on Charles River Laboratories to $205 From $220, Maintains Equalweight Rating	Nov. 10	MT
UBS Cuts Charles River Laboratories International Price Target to $215 From $250, Maintains Buy Rating	Nov. 09	MT
Deutsche Bank Adjusts Charles River Laboratories International Price Target to $215 From $236, Maintains Buy Rating	Nov. 09	MT
Morgan Stanley Cuts Charles River Laboratories International's Price Target to $220 From $235, Keeps Equalweight Rating	23-10-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Analyst Reco.

Filters